Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation. spravato_annual_worldwide_sales_2019_2026 More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis while searching for a safer anesthetic, the molecule has completed its migration into psychiatry, where it has become a blockbuster. Esketamine, the more potent S-enantiomer of that original compound, won FDA approval for treatment-resistant depression as a nasal spray in March 2019, then only as an add-on to a conventional antidepressant. In January 2025, regulators cleared it as the only monotherapy for treatment-resistant depression . After a quiet start following…
spravato_annual_worldwide_sales_2019_2026More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis while searching for a safer anesthetic, the molecule has completed its migration into psychiatry, where it has become a blockbuster. Esketamine, the more potent S-enantiomer of that original compound, won FDA approval for treatment-resistant depression as a nasal spray in March 2019, then…
The post J&J poster puts Spravato remission data at center of treatment-resistant-depression growth push appeared first on Drug Discovery and Development.
US Pharma Marketing